The new legislation also builds on White House infrastructure goals to improve health care, drug development and more.
Leaders across the Center for Drug Evaluation and Research are applying lessons learned from the pandemic on its response to therapies for emerging variants.
FDA leaders are experimenting on new programs that innovate how technology facilitates the review and approval of new drugs.
The office’s director explains how it has leveraged new practices to quickly review and approve treatments amid the COVID-19 pandemic.
The acting CIO shared insights into the agency's pandemic response and lessons learned so far.